Goldforb et al. described the case of a 50-year-old woman with 100% PD-L1-positive choriocarcinoma treated with Pembrolizumab who showed consistent disease progression following six treatment regimens: EMA/CO for 11 cycles, EMA/EP for 5 cycles, TP/TE for 7 cycles, FAEV for 4 cycles, ICE for 4 cycles and TCR105, a monoclonal antibody to endoglin, for 4 cycles). Here, ENG is linked to choriocarcinoma.